Video
Dr. Balar Discusses KEYNOTE-057 Study in NMIBC
Author(s):
In Partnership With:
Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 study presented at the 2019 Genitourinary Cancers Symposium.
Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 trial presented at the 2019 Genitourinary Cancers Symposium.
For the trial, investigators evaluated the use of pembrolizumab (Keytruda) in patients with high-risk non—muscle invasive bladder cancer (NMIBC) who previously received Bacillus Calmette-Guérin (BCG), an intravesical immunotherapy, and became unresponsive to the treatment. Balar presented data from cohort A of the trial, which was comprised of 102 patients with carcinoma in situ with or without papillary disease.
At a median follow-up of approximately 16 months, complete response rate in the bladder with the PD-1 inhibitor was 40%, Balar says. In addition, median duration of response at the time of presentation was approximately 12.5 months. Further, about 53% of patients will have complete responses lasting 9 months or longer, says Balar. Although these are encouraging data, he adds, longer follow-up data will be necessary.
